Stay tuned for a single dose Corona vaccine that will change the rules of the game – Covid-19

Chief advisor to Operation Warp Speed, which aims to speed up production of emerging coronavirus vaccines, Mansaf Salawi, has revealed that the vaccine Johnson & Johnson has been working on in development could see the light of day next February. it is approved on the scheduled date.

The Johnson & Johnson vaccine differs from the “Pfizer” and “Moderna” vaccines in several respects, notably the fact that it consists of only one dose, whereas the vaccines available so far must receive two doses. with an interval of up to two weeks.

It completely changes the rules of the game

Al-Sallawi has said the Johnson & Johnson vaccine could be a game-changer in the face of the pandemic. We hope that this vaccine, consisting of a single dose, will be equivalent to the effectiveness (of the vaccines) of Moderna and Pfizer.

“We are increasingly confident that the efficacy review (of the Johnson & Johnson vaccine) will take place in January,” he added.

Al-Salawi suggested the company would request emergency use of its vaccine in January and that it would be obtained no later than the first half of next February.

The Johnson & Johnson vaccine is expected to achieve faster access to the preventive peak stage in a period of no more than weeks, as it does not need another dose weeks after receiving the first like the rest of the vaccines, according to Al Hurra.

Johnson & Johnson recently revealed that they are ready to begin the final stages of trials of their emerging coronavirus vaccine and said they expect data on trial progress to appear at the end of next january.

Johnson & Johnson recently managed to recruit 45,000 volunteers to participate in clinical trials of its vaccine.

According to the company statement, the high rate of Corona infection in the countries where its experiments are being carried out has made it difficult to attract more volunteers.

The United States agreed with Johnson & Johnson to buy 100 million doses of its vaccine, and the deal included an option to purchase an additional 200 million doses.